Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Albireo Pharma Inc.

https://www.albireopharma.com/

Latest From Albireo Pharma Inc.

CymaBay Appears Stronger Threat To Ocaliva In PBC Than Ipsen/Genfit

CymaBay and Genfit have been positioning their failed NASH candidates, both PPAR agonists, for approval in second-line primary biliary cholangitis. Analysts call both approvable, but say CymaBay’s drug has a better overall profile.

Business Strategies Clinical Trials

Ipsen Buoyant Despite EMA’s Bylvay Orphan Status Block

The French company plans to refile Bylvay for Alagille syndrome under a new brand name after the EMA's Committee for Orphan Medicinal Products said the drug did not meet its 'significant benefit' criteria.

Sales & Earnings Business Strategies

Ipsen's Desire For Dealmaking Burns Bright

CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."

Business Strategies Commercial

Business Development Remains Top Priority For Ipsen

CEO David Loew tells Scrip that Ipsen’s prodigious dealmaking over the past couple of years is set to continue, on top of the acquisition of Albireo announced last month.

Sales & Earnings Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Albireo AB
    • Biodel Inc.
UsernamePublicRestriction

Register